

中國醫藥大學附殺醫院

CHINA MEDICAL UNIVERSITY HOSPITAL

台中市北區育德路2號

2 Yude Road, Taichung, 40447, Taiwan (R.O.C.)

TEL: 886-4-22052121

Research Ethics Committee China Medical University & Hospital, Taichung, Taiwan

Tel: 886-4-22052121 ext: 1925 Fax: 886-4-2207-1478

Clinical Trial/Human Research Approval

Date: Jan. 20, 2020

Protocol Title: Clinical course and outcome in Asian patients with basilar artery occlusion treated

conventionally

Protocol No. / CMUH REC No.: / CMUH109-REC2-003

Name of Principal Investigator: Sheng-Ta Tsai (Attending Physician, Neurology Department)

Name of Institution: China Medical University Hospital

<u>Date of Approval</u>: Jan. 18, 2020 <u>Date of Expiration</u>: Jan. 17, 2021

Protocol: Version 01, Date: Jan. 01, 2020

<u>Chinese Synopsis</u>: Version 01, Date: Jan. 01, 2020 <u>English Synopsis</u>: Version 01, Date: Jan. 01, 2020

DSMP: Version 01, Date: 2019/12/25

Frequency of Continuing Review: Once per every 12 months

This is to certify that the above referenced research project has been expedited approved by the Research Ethics Committee (REC) II of the China Medical University and Hospital on Jan. 18, 2020. The REC is organized under, and operates in accordance with, the Good Clinical Practices guidelines and the governmental laws and regulations. The frequency of continuing review for the research project determined by the REC is mentioned above. Please submit a completed progress report at least two months before the time at which continuing review must occur.

All the amendments to the research project should be re-submitted and approved by the REC BEFORE implementation. Also, the principal investigator is required to report all serious adverse events and unanticipated problems involving risks to the subjects or others on time.

Martin M-T Fuh MD, DMSci.

Chairman, Research Ethics Committee II

China Medical University & Hospital

